LAGUNA HILLS, Calif., Dec. 19 /PRNewswire/ -- CODA Genomics announced today an expansion of its collaboration with Viventia Biotech (Mississauga, Ontario). As part of the expanded relationship, CODA will apply its proprietary Translational Engineering(TM) protein expression solutions to various antibody projects within Viventia.
"We are pleased to continue an expanded relationship with Viventia. The growing level of interest and impact of protein Translational Engineering(TM) on the pipelines of pharmaceutical companies validates our unique protein expression solutions," said Alan Carter, Senior Vice President of Business Development. Dr. Robert J. Molinari, CEO of CODA added, "These relationships are an important part of CODA demonstrating the enormous value of its Translational Engineering technology to virtually any biologic drug discovery process."
CODA's proprietary protein translation technologies address protein expression, solubility and activity challenges in rational design steps at all stages of pharmaceutical development. This important, revolutionary utilization of synthetic biology is changing the competitive landscape of many businesses which rely on successful protein production.
Terms of the relationships were not disclosed.
About CODA Genomics, Inc.
CODA Genomics, Inc. is a protein Translation Engineering(TM) company focused on proprietary, patented approaches to express proteins across a variety of eukaryotic and prokaryotic cell lines. This unique technology enables synthetic biology success by solving problems related to protein expression, activity and solubility.
CODA Genomics, Inc.CONTACT: Alan Carter of CODA Genomics, Inc., +1-949-305-5505,acarter@codagenomics.com
Web site: http://www.codagenomics.com/
